TY - JOUR
T1 - RenalGuard system in high-risk patients for contrast-induced acute kidney injury
AU - Briguori, Carlo
AU - Visconti, Gabriella
AU - Donahue, Michael
AU - De Micco, Francesca
AU - Focaccio, Amelia
AU - Golia, Bruno
AU - Signoriello, Giuseppe
AU - Ciardiello, Carmine
AU - Donnarumma, Elvira
AU - Condorelli, Gerolama
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target. Methods Four hundred consecutive patients with an estimated glomerular filtration rate ≤30 mL/min per 1.73 m2 and/or a high predicted risk (according to the Mehran score ≥11 and/or the Gurm score >7%) treated by the RenalGuard therapy were analyzed. The primary end points were (1) the relationship between CI-AKI and UFR during preprocedural, intraprocedural, and postprocedural phases of the RenalGuard therapy and (2) the rate of acute pulmonary edema and impairment in electrolytes balance. Results Urine flow rate was significantly lower in the patients with CI-AKI in the preprocedural phase (208 ± 117 vs 283 ± 160 mL/h, P 0.32 mg/kg (HR 5.03, 95% CI 2.33-10.87, P
AB - Background High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target. Methods Four hundred consecutive patients with an estimated glomerular filtration rate ≤30 mL/min per 1.73 m2 and/or a high predicted risk (according to the Mehran score ≥11 and/or the Gurm score >7%) treated by the RenalGuard therapy were analyzed. The primary end points were (1) the relationship between CI-AKI and UFR during preprocedural, intraprocedural, and postprocedural phases of the RenalGuard therapy and (2) the rate of acute pulmonary edema and impairment in electrolytes balance. Results Urine flow rate was significantly lower in the patients with CI-AKI in the preprocedural phase (208 ± 117 vs 283 ± 160 mL/h, P 0.32 mg/kg (HR 5.03, 95% CI 2.33-10.87, P
UR - http://www.scopus.com/inward/record.url?scp=84960343994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960343994&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2015.12.005
DO - 10.1016/j.ahj.2015.12.005
M3 - Article
C2 - 26920598
AN - SCOPUS:84960343994
VL - 173
SP - 67
EP - 76
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
ER -